Inhibikase Therapeutics’ $10 Million Direct Offering and Private Placements

McDermott Will & Emery represented Inhibikase Therapeutics, Inc. in the transaction.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course…